Journal: Cells

Article Title: The Effect of Ursodeoxycholic Acid (UDCA) on Serum Expression of miR-34a and miR-506 in Patients with Chronic Cholestatic Liver Diseases

doi: 10.3390/cells14151137

Figure Lengend Snippet: Basal serum expression levels of miR-34a and miR-506 in patients with PBC and PSC before the introduction of UDCA treatment. miR-34a ( A ) expression was significantly elevated in PBC patients compared to age- and sex-matched healthy controls, while no significant difference was observed in PSC patients due to high intra-group variability. miR-506 ( B ) expression was markedly elevated—by several-dozen-fold—in PBC patients relative to controls. Comparisons between experimental groups were performed using the Mann–Whitney U test. Data are presented as mean ± SEM. Abbreviations: PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; UDCA, ursodeoxycholic acid.

Article Snippet: The levels of miR-34a (478048_mir) and miR-506 (478958_mir), along with miR-16 (477860_mir), which was used as an endogenous control, were measured using TaqMan ® Advanced miRNA Assays (Applied Biosystems).

Techniques: Expressing, MANN-WHITNEY

Journal: Cells

Article Title: The Effect of Ursodeoxycholic Acid (UDCA) on Serum Expression of miR-34a and miR-506 in Patients with Chronic Cholestatic Liver Diseases

doi: 10.3390/cells14151137

Figure Lengend Snippet: The effect of UDCA treatment on the serum expression of miR-34a and miR-506. UDCA suppressed the expression of miR-34a ( A ) and miR-506 ( C ) in patients with PBC but not PSC ( B ). Each symbol represents one patient. A Student’s paired t -test was used to test statistical significance. The median duration of UDCA administration was 44 months (range: 22–56 months). PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; UDCA naive, values before the introduction of ursodeoxycholic acid; UDCA, after treatment with UDCA.

Article Snippet: The levels of miR-34a (478048_mir) and miR-506 (478958_mir), along with miR-16 (477860_mir), which was used as an endogenous control, were measured using TaqMan ® Advanced miRNA Assays (Applied Biosystems).

Techniques: Expressing

Journal: Cells

Article Title: The Effect of Ursodeoxycholic Acid (UDCA) on Serum Expression of miR-34a and miR-506 in Patients with Chronic Cholestatic Liver Diseases

doi: 10.3390/cells14151137

Figure Lengend Snippet: Effects of UDCA on LPS-induced expression of TREM-2, miR-34a, and ADAM17 in NHC cell lines. qPCR analysis demonstrated that TREM-2 ( A ) was not induced by LPS stimulation alone; however, co-treatment with UDCA resulted in activation of this gene. The LPS-induced expression of miR-34a ( B ) and ADAM17 ( C ) mRNA was significantly suppressed by co-treatment with UDCA. Data are presented as mean ± SEM from four independent experiments. Statistical analysis was performed using two-way ANOVA followed by Fisher’s least significant difference (LSD) test. Abbreviations: ADAM17, a disintegrin and metalloprotease 17; LPS, lipopolysaccharide from Escherichia coli; NHC, normal human cholangiocytes; TREM-2, triggering receptor expressed on myeloid cells 2; UDCA, ursodeoxycholic acid.

Article Snippet: The levels of miR-34a (478048_mir) and miR-506 (478958_mir), along with miR-16 (477860_mir), which was used as an endogenous control, were measured using TaqMan ® Advanced miRNA Assays (Applied Biosystems).

Techniques: Expressing, Activation Assay